Financiado en parte por Bristol-Myers Squibb, Pfizer
Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy
Cholesterol Treatment Trialists' (CTT) Collaboration, Emberson JR, Kearney PM, Blackwell L, Newman C, Reith C, Bhala N, Holland L, Peto R, Keech A, Collins R, Simes J, Baigent C
PloS one · 254 citas
Etiquetas de revisión
Financiado por la industriaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Metaanálisis (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Eventos clínicos como enfermedad o muerte
Quién lo pagó
- Financiación
- Financiado por la industria
- Empresa
- Bristol-Myers Squibb
- Empresa
- Pfizer
- Organización sin fines de lucro
- Cancer Research UK
- Organización sin fines de lucro
- British Heart Foundation
- Organización sin fines de lucro
- BHF Centre of Research Excellence, Oxford
- Gobierno
- Medical Research Council
- Gobierno
- National Health and Medical Research Council
- Subvenciones
- BHF Centre of Research Excellence, Oxford (RE/08/04); British Heart Foundation (RE/08/04)
Según 7 financiadores declarados.
Publicación
- Publicado
- 2012-01-19 · PLoS One · vol. 7 · número 1 · pág. e29849
- Editorial
- Public Library of Science
- Citado
- 351 citas · más que el 89% de estudios similares · 2.1× el promedio de su campo
- Referencias
- 30 trabajos
- Acceso
- Acceso abierto (revista) · CC-BY
- Áreas de investigación
- Cancer, Lipids, and Metabolism · Lipoproteins and Cardiovascular Health · Metabolism, Diabetes, and Cancer
- Palabras clave
- statin therapy, LDL cholesterol lowering, cancer incidence, cancer mortality, statin safety, individual patient data, cardiovascular disease prevention, subgroup analysis, individual patient data meta-analysis
- MeSH
- humans, neoplasms, anticholesteremic agents, hydroxymethylglutaryl-coa reductase inhibitors, cholesterol, ldl, randomized controlled trials as topic
1 autor
- Cholesterol Treatment Trialists' (CTT) Collaboration🇬🇧 · autor de correspondenciaUniversity of Oxford
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
Statin therapy reduces the risk of occlusive vascular events, but uncertainty remains about potential effects on cancer. We sought to provide a detailed assessment of any effects on cancer of lowering LDL cholesterol (LDL-C) with a statin using individual patient records from 175,000 patients in 27 large-scale statin trials.
Methods and findings
Individual records of 134,537 participants in 22 randomised trials of statin versus control (median duration 4.8 years) and 39,612 participants in 5 trials of more intensive versus less intensive statin therapy (median duration 5.1 years) were obtained. Reducing LDL-C with a statin for about 5 years had no effect on newly diagnosed cancer or on death from such cancers in either the trials of statin versus control (cancer incidence: 3755 [1.4% per year [py]] versus 3738 [1.4% py], RR 1.00 [95% CI 0.96-1.05]; cancer mortality: 1365 [0.5% py] versus 1358 [0.5% py], RR 1.00 [95% CI 0.93-1.08]) or in the trials of more versus less statin (cancer incidence: 1466 [1.6% py] vs 1472 [1.6% py], RR 1.00 [95% CI 0.93-1.07]; cancer mortality: 447 [0.5% py] versus 481 [0.5% py], RR 0.93 [95% CI 0.82-1.06]). Moreover, there was no evidence of any effect of reducing LDL-C with statin therapy on cancer incidence or mortality at any of 23 individual categories of sites, with increasing years of treatment, for any individual statin, or in any given subgroup. In particular, among individuals with low baseline LDL-C (<2 mmol/L), there was no evidence that further LDL-C reduction (from about 1.7 to 1.3 mmol/L) increased cancer risk (381 [1.6% py] versus 408 [1.7% py]; RR 0.92 [99% CI 0.76-1.10]).
Conclusions
In 27 randomised trials, a median of five years of statin therapy had no effect on the incidence of, or mortality from, any type of cancer (or the aggregate of all cancer).
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.